title: Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series.
abstract: BACKGROUND
  Randomized clinical trials showed the benefit of adjuvant trastuzumab-based chemotherapy (ATBC) for node-positive and/or >1 cm HER2+ breast carcinomas. No efficacy data have been published on ATBC in large series of pT1abN0 HER2+ tumors.
  
  
  METHODS
  This retrospective study evaluated 276 cases of pT1abN0 HER2+ breast tumors in eight French cancer centers. Factors associated with prognosis and ATBC prescription were analyzed.
  
  
  RESULTS
  A total of 129 cases (47%) were treated with ATBC (ATBC+), 19 with chemotherapy alone, 5 with trastuzumab alone, and 123 (45%) with neither trastuzumab nor chemotherapy (ATBC-). ATBC use was associated with the date of diagnosis (before or after June 2005) and with poor prognostic features. At a median follow-up of 44 months, there were 13 recurrences in the ATBC- group and 2 in the ATBC+ group. ATBC was associated with a significant survival benefit (99% 40-month disease-free survival for ATBC+ versus 93% for ATBC- cases; P = 0.018). Lack of hormone receptors (HRs) and the presence of lymphovascular invasion (LVI) were significantly associated with a poor prognosis and a greater benefit of ATBC.
  
  
  CONCLUSIONS
  ATBC was associated with a significantly reduced risk of recurrence in pT1abN0 HER2+ tumors, and was more beneficial in HR- and/or LVI+ tumors.
authors.affiliation: Department of Medical Oncology, Institut Curie, 26, rue d’Ulm, 75248 Paris Cedex 05, France.
authors.forename: M J
authors.initials: MJ
authors.lastname: Rodrigues
authors.forename: J
authors.initials: J
authors.lastname: Peron
authors.forename: J-S
authors.initials: JS
authors.lastname: Frénel
authors.forename: Y-A
authors.initials: YA
authors.lastname: Vano
authors.forename: J
authors.initials: J
authors.lastname: Wassermann
authors.forename: M
authors.initials: M
authors.lastname: Debled
authors.forename: F
authors.initials: F
authors.lastname: Picaud
authors.forename: L
authors.initials: L
authors.lastname: Albiges
authors.forename: A
authors.initials: A
authors.lastname: Vincent-Salomon
authors.forename: P H
authors.initials: PH
authors.lastname: Cottu
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D002277:Carcinoma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D011960:Receptors, Estrogen; D012189:Retrospective Studies; D012307:Risk Factors; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D011960:Receptors, Estrogen; D000068878:Trastuzumab